Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis

NCT05776940 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

116

Enrollment

OTHER

Sponsor class

Conditions

Immunoglobulin Light-chain Amyloidosis

Interventions

DRUG: Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab
DRUG: Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab

Sponsor

Air Force Military Medical University, China